147 related articles for article (PubMed ID: 9628546)
21. Clinical effects of raloxifene hydrochloride in women.
Khovidhunkit W; Shoback DM
Ann Intern Med; 1999 Mar; 130(5):431-9. PubMed ID: 10068418
[TBL] [Abstract][Full Text] [Related]
22. Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat.
Martel C; Picard S; Richard V; Bélanger A; Labrie C; Labrie F
J Steroid Biochem Mol Biol; 2000 Sep; 74(1-2):45-56. PubMed ID: 11074355
[TBL] [Abstract][Full Text] [Related]
23. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles.
Baker VL; Draper M; Paul S; Allerheiligen S; Glant M; Shifren J; Jaffe RB
J Clin Endocrinol Metab; 1998 Jan; 83(1):6-13. PubMed ID: 9435408
[TBL] [Abstract][Full Text] [Related]
24. Raloxifene: a selective estrogen receptor modulator.
Scott JA; Da Camara CC; Early JE
Am Fam Physician; 1999 Sep; 60(4):1131-9. PubMed ID: 10507743
[TBL] [Abstract][Full Text] [Related]
25. Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model.
Neubauer BL; Best KL; Counts DF; Goode RL; Hoover DM; Jones CD; Sarosdy MF; Shaar CJ; Tanzer LR; Merriman RL
Prostate; 1995 Oct; 27(4):220-9. PubMed ID: 7479389
[TBL] [Abstract][Full Text] [Related]
26. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
Palkowitz AD; Glasebrook AL; Thrasher KJ; Hauser KL; Short LL; Phillips DL; Muehl BS; Sato M; Shetler PK; Cullinan GJ; Pell TR; Bryant HU
J Med Chem; 1997 May; 40(10):1407-16. PubMed ID: 9154963
[TBL] [Abstract][Full Text] [Related]
27. Raloxifene, a new selective estrogen receptor modulator.
Goldfrank D; Haytoglu T; Frishman WH; Mohammad Z
J Clin Pharmacol; 1999 Aug; 39(8):767-74. PubMed ID: 10434227
[TBL] [Abstract][Full Text] [Related]
28. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model.
Ke HZ; Chen HK; Simmons HA; Qi H; Crawford DT; Pirie CM; Chidsey-Frink KL; Ma YF; Jee WS; Thompson DD
Bone; 1997 Jan; 20(1):31-9. PubMed ID: 8988345
[TBL] [Abstract][Full Text] [Related]
29. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.
Armamento-Villareal R; Sheikh S; Nawaz A; Napoli N; Mueller C; Halstead LR; Brodt MD; Silva MJ; Galbiati E; Caruso PL; Civelli M; Civitelli R
J Bone Miner Res; 2005 Dec; 20(12):2178-88. PubMed ID: 16294271
[TBL] [Abstract][Full Text] [Related]
30. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
Qu Q; Zheng H; Dahllund J; Laine A; Cockcroft N; Peng Z; Koskinen M; Hemminki K; Kangas L; Väänänen K; Härkönen P
Endocrinology; 2000 Feb; 141(2):809-20. PubMed ID: 10650964
[TBL] [Abstract][Full Text] [Related]
31. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits.
Bjarnason NH; Haarbo J; Byrjalsen I; Kauffman RF; Christiansen C
Circulation; 1997 Sep; 96(6):1964-9. PubMed ID: 9323087
[TBL] [Abstract][Full Text] [Related]
32. Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats.
Nuttall ME; Bradbeer JN; Stroup GB; Nadeau DP; Hoffman SJ; Zhao H; Rehm S; Gowen M
Endocrinology; 1998 Dec; 139(12):5224-34. PubMed ID: 9832463
[TBL] [Abstract][Full Text] [Related]
33. Effects of oral estrogen, raloxifene and arzoxifene on gene expression in serotonin neurons of macaques.
Bethea CL; Mirkes SJ; Su A; Michelson D
Psychoneuroendocrinology; 2002 May; 27(4):431-45. PubMed ID: 11911997
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators.
Fuchs-Young R; Howe S; Hale L; Miles R; Walker C
Mol Carcinog; 1996 Nov; 17(3):151-9. PubMed ID: 8944075
[TBL] [Abstract][Full Text] [Related]
35. Effects of 3-phenyl-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]- 2H-1-benzopyran-7-ol (CHF 4056), a novel nonsteroidal estrogen agonist/antagonist, on reproductive and nonreproductive tissue.
Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
J Pharmacol Exp Ther; 2002 Mar; 300(3):802-9. PubMed ID: 11861784
[TBL] [Abstract][Full Text] [Related]
36. [Estrogen receptor and selective estrogen receptor modulators (SERMs)].
Shioi A; Nishizawa Y
Nihon Rinsho; 1999 May; 57(5):1199-207. PubMed ID: 10361456
[TBL] [Abstract][Full Text] [Related]
37. Sensitivity of a Tier I screening battery compared to an in utero exposure for detecting the estrogen receptor agonist 17 beta-estradiol.
O'Connor JC; Frame SR; Biegel LB; Cook JC; Davis LG
Toxicol Sci; 1998 Aug; 44(2):169-84. PubMed ID: 9742655
[TBL] [Abstract][Full Text] [Related]
38. Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo.
Sömjen D; Waisman A; Kaye AM
J Steroid Biochem Mol Biol; 1996 Dec; 59(5-6):389-96. PubMed ID: 9010344
[TBL] [Abstract][Full Text] [Related]
39. Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats.
Sato M; Bryant HU; Iversen P; Helterbrand J; Smietana F; Bemis K; Higgs R; Turner CH; Owan I; Takano Y; Burr DB
J Pharmacol Exp Ther; 1996 Oct; 279(1):298-305. PubMed ID: 8859007
[TBL] [Abstract][Full Text] [Related]
40. Molecular determinants of tissue selectivity in estrogen receptor modulators.
Grese TA; Sluka JP; Bryant HU; Cullinan GJ; Glasebrook AL; Jones CD; Matsumoto K; Palkowitz AD; Sato M; Termine JD; Winter MA; Yang NN; Dodge JA
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):14105-10. PubMed ID: 9391160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
